Five Prime Thera (FPRX) Stock News
NASDAQ:FPRX - Nasdaq -
FPRX Latest News, Press Relases and Analysis
Amgen Successfully Completes Acquisition Of Five Prime Therapeutics
Mentions: AMGN
Lifshitz Law Firm, P.C. Announces Investigation of ATH, WIFI, BMTC, WSFS, DSSI, INSW, FPRX, FI, HWCC, and RMBL
Earnings Outlook for Five Prime Therapeutics
Five Prime Therapeutics (NASDAQ:FPRX) releases its next round of earnings this Wednesday, March 10. Get the latest predictions in Benzinga's essential guide to the company...
Is Amgen's Acquisition of Five Prime a Good Move for the Big Biotech?
The drugmaker needs as much potential revenue as it can acquire at a reasonable price.
Mentions: AMGN
Benefitfocus and Five Prime Therapeutics See Analyst Action
Indaba Capital wants a board “refresh” at benefits-management software firm Benefitfocus. Magnetar Capital disclosed a large stake in biopharmaceutical firm Prime Therapeutics.
Though Potential Bidders Moved Away, Amgen's Bid For Five Prime Outlasted 15 Suitors
Earlier this month, biotech giant Amgen Inc (NASDAQ: AMGN) announced a $1.9 billion buyout of Five Prime Therapeutics Inc (NASDAQ: FPRX)...
Mentions: AMGN
Five Prime Cancels Fourth Quarter and Full-Year 2020 Financial Results Conference Call
SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Five Prime Therapeutics, Inc. - FPRX
Moore Kuehn Encourages FPRX, SVBI, SOAC, and CAP Investors to Contact Law Firm
Amgen Acquires a Cancer Drug. Expect More Deals.
The biotech firm is building its pipeline by adding an experimental drug that could compete against Bristol Myers Squibb in treating deadly stomach cancers.
ALERT: Halper Sadeh LLP Investigates SVBI, FPRX, MIK, JCS; Shareholders are Encouraged to Contact the Firm
SHAREHOLDER ALERT: WeissLaw LLP Investigates Five Prime Therapeutics, Inc.
Mentions: AMGN
Amgen to Buy Oncology Start-Up Five Prime Therapeutics for $1.9 Billion
The big biotech wants to bolster its late-stage pipeline with a potential new stomach cancer treatment.
Mentions: AMGN